Power considerations for clinical trials using multivariate time-to-event data

被引:0
|
作者
Hughes, MD [1 ]
机构
[1] HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115
关键词
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many clinical trials involve the collection of data on the times to occurrence of different types of events, such as different fungal infections in AIDS research, or of recurrences of the same type, such as successive fits in epilepsy research. The multivariate proportional hazards model allows for analysis of this data and software for doing this is now widely available. In this paper, the approximate power of a clinical trial that aims to use such data for comparing two treatments is derived. Special attention is given to the bivariate case, both to show that the approximation works well and to illustrate how various design parameters affect the power of a trial. As with any multivariate data in clinical trials, there are many conceptual issues that should be considered during trial design; the paper closes with a discussion of some of these. (C) 1997 by John Wiley & Sons, Ltd. Stat. Med., Vol. 16, 865-882 (1997).
引用
收藏
页码:865 / 882
页数:18
相关论文
共 50 条
  • [31] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    [J]. CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396
  • [32] Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
    Uno, Hajime
    Schrag, Deborah
    Kim, Dae Hyun
    Tang, Dejun
    Tian, Lu
    Rugo, Hope S.
    Wei, Lee-Jen
    [J]. JNCI CANCER SPECTRUM, 2019, 3 (04)
  • [33] Meta-analysis of clinical trials with competing time-to-event endpoints
    Meddis, Alessandra
    Latouche, Aurelien
    Zhou, Bingqing
    Michiels, Stefan
    Fine, Jason
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (03) : 712 - 723
  • [34] AN APPROACH FOR JOINTLY MODELING MULTIVARIATE LONGITUDINAL MEASUREMENTS AND DISCRETE TIME-TO-EVENT DATA
    Albert, Paul S.
    Shih, Joanna H.
    [J]. ANNALS OF APPLIED STATISTICS, 2010, 4 (03): : 1517 - 1532
  • [35] Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpoints
    Madan G. Kundu
    Sandipan Samanta
    Shoubhik Mondal
    [J]. Health Services and Outcomes Research Methodology, 2024, 24 : 14 - 45
  • [36] Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpoints
    Kundu, Madan G.
    Samanta, Sandipan
    Mondal, Shoubhik
    [J]. HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY, 2024, 24 (01) : 14 - 45
  • [37] Analysis of Time-to-Event Data Under a Two-Stage Survival Adaptive Design in Clinical Trials
    Lu, Qingshu
    Tse, Siu Keung
    Chow, Shein-Chung
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2010, 20 (04) : 705 - 719
  • [38] SAMPLE SIZE DETERMINATION IN SHARED FRAILTY MODELS FOR MULTIVARIATE TIME-TO-EVENT DATA
    Chen, Liddy M.
    Ibrahim, Joseph G.
    Chu, Haitao
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (04) : 908 - 923
  • [39] Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
    Eliana Rulli
    Francesca Ghilotti
    Elena Biagioli
    Luca Porcu
    Mirko Marabese
    Maurizio D’Incalci
    Rino Bellocco
    Valter Torri
    [J]. British Journal of Cancer, 2018, 119 : 1456 - 1463
  • [40] Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information
    Wang, Jianming
    Ke, Chunlei
    Yu, Zhinuan
    Fu, Lei
    Dornseif, Bruce
    [J]. PHARMACEUTICAL STATISTICS, 2016, 15 (03) : 198 - 207